Depemokimab

GSK will showcase 43 abstracts at the ATS 2025 International Congress, highlighting advancements in treatments for asthma and COPD with mepolizumab and depemokimab.

Moderna and Merck's mRNA-4157 combined with pembrolizumab significantly reduced melanoma recurrence risk by 44% compared to pembrolizumab alone, marking a leap in personalized cancer treatment.

The European Medicines Agency (EMA) has accepted GSK's application for depemokimab as an add-on treatment for asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

AstraZeneca and Amgen's Tezspire met the primary endpoint in a Phase III trial, significantly reducing nasal polyp size in patients with chronic rhinosinusitis.

DelveInsight reports a robust severe asthma pipeline with over 50 therapies in development by more than 40 companies, targeting unmet needs in this challenging condition.